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Consumption of isoflavone-rich soyabean protein is reported to reduce total and LDL-cholesterol, but the 
specific components responsible are undetermined. In a previous crossover trial we showed that purified 
isoflavones, derived from red clover (Trifolium pratense), raised HDL3-cholesterol in premenopausal 
women; however, these findings were inconclusive due to period and carryover effects. In an attempt to 
overcome this problem, we utilised a parallel study designed to re-examine the effects of purified 
isoflavones on plasma lipoproteins and markers of insulin resistance in premenopausal women. Twenty-
five healthy premenopausal women participated in a double-blind, randomised, parallel study. The 
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supplement for four menstrual cycles. Blood samples were collected weekly during cycles 1, 3 and 4. 
Supplementation with isoflavones resulted in a 15-fold increase in urinary isoflavone excretion 
(P<0·0001). There were no significant effects on total cholesterol, LDL- and HDL-cholesterol, HDL 
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that purified isoflavones derived from red clover have no effect on cholesterol homeostasis or insulin 
resistance in premenopausal women, a group which is at low risk of CHD. 
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Consumption of isoflavone-rich soyabean protein is reported to reduce total and LDL-cholesterol,
but the specific components responsible are undetermined. In a previous crossover trial we
showed that purified isoflavones, derived from red clover (Trifolium pratense ), raised HDL3-
cholesterol in premenopausal women; however, these findings were inconclusive due to period
and carryover effects. In an attempt to overcome this problem, we utilised a parallel study
designed to re-examine the effects of purified isoflavones on plasma lipoproteins and markers
of insulin resistance in premenopausal women. Twenty-five healthy premenopausal women par-
ticipated in a double-blind, randomised, parallel study. The treatment group (n 12) consumed a
placebo for the first menstrual cycle and an isoflavone supplement (86 mg/d, derived from red
clover) for three cycles, while the placebo group (n 13) consumed a placebo supplement for
four menstrual cycles. Blood samples were collected weekly during cycles 1, 3 and 4. Sup-
plementation with isoflavones resulted in a 15-fold increase in urinary isoflavone excretion
(P,0·0001). There were no significant effects on total cholesterol, LDL- and HDL-cholesterol,
HDL subfractions, triacylglycerol, lipoprotein(a), glucose or insulin concentrations. Our present
results indicate that purified isoflavones derived from red clover have no effect on cholesterol
homeostasis or insulin resistance in premenopausal women, a group which is at low risk of CHD.
Isoflavones: Lipids: Premenopausal women
Clinical trials in human subjects have demonstrated the ben-
eficial effects of substituting soyabean protein for animal
protein in modifying cardiovascular risk factors (Carroll,
1991; Anderson et al. 1995). However, the specific
component(s) responsible for the hypocholesterolaemic
properties of soyabean protein are yet to be determined
(Potter, 1998). Intervention studies with isoflavone-rich
soyabean protein, compared with isoflavone-free soyabean
protein, in animals and human subjects have shown
reductions in total cholesterol and LDL-cholesterol
(Anthony et al. 1996, 1997; Kirk et al. 1998; Crouse et al.
1999; Merz-Demlow et al. 2000), and increases (Anthony
et al. 1996, 1997) or no alterations (Kirk et al. 1998;
Crouse et al. 1999; Merz-Demlow et al. 2000) in HDL-
cholesterol. These observations may have led to the hypoth-
esis that isoflavones produce a favourable lipoprotein profile.
The postulated mechanism by which isoflavones influ-
ence lipoprotein metabolism is related to their structural
similarity to oestrogen. Isoflavones possess weak oestro-
genic activity and low affinity binding for oestrogen recep-
tors (Markiewicz et al. 1993; Milligan et al. 1998).
Oestrogens have been shown to lower plasma total choles-
terol and LDL-cholesterol (Tikkanen 1996), possibly due
to up-regulation of LDL-receptor activity (Abbey et al.
1999), and raise HDL-cholesterol, probably due to reduction
in hepatic lipase activity and increase the synthesis of apo-
lipoprotein A-I (Muesing et al. 1992; Brinton, 1996;
Lamon-Fava et al. 1999). Similarly, isoflavones (Kanuck
& Ellworth, 1995) and/or soyabean protein (Khosla et al.
1991; Baum et al. 1998) have also been associated with
up-regulation of LDL-receptors and increased apolipopro-
tein A-I synthesis (Lamon-Fava, 2000).
In elucidating the mechanism by which isoflavones influ-
ence cholesterol metabolism, we conducted a placebo-con-
trolled crossover trial with purified isoflavones, derived
from red clover (Trifolium pratense ), in premenopausal
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women. We have previously observed that isoflavones
increased HDL3-cholesterol concentrations, which contin-
ued to increase during the subsequent crossover to placebo
and remained 11 % greater than baseline values at the end
of the study (Samman et al. 1999). However, these findings
were inconclusive, due to the observed period and carryover
effects, which reduced the power of the study. The possibility
that oestrogenic activity of isoflavones could increase HDL-
cholesterol concentrations is consistent with the known
effects of oestrogens on cholesterol homeostasis (Muesing
et al. 1992; Brinton, 1996; Lamon-Fava et al. 1999).
The aim of the present study was to explore further the
effects of purified isoflavones, derived from red clover, on
plasma lipoproteins and insulin resistance in premenopausal
women.
Methods
Subjects
Females aged 18–45 years were invited to participate in the
study by advertisements in The University of Sydney News-
letter and local district newspapers. Prospective subjects
were interviewed over the telephone and in person, and
completed a medical history and lifestyle questionnaire.
Subjects were included in the study if they met the follow-
ing criteria: a regular menstrual cycle; no history of chronic
illness, hyperlipidaemia or a family history of cancer, liver,
gall bladder, bowel or kidney disease; not taking medication
that influences lipid metabolism; not taking antibiotics, oral
contraceptive agents, steroids or isoflavone supplements;
stable dietary intake, weight and/or exercise regimens; con-
suming less than one serving of foods rich in isoflavones per
week. The study protocol was approved by The University
of Sydney Human Ethics Review Committee and partici-
pants provided written informed consent prior to the
commencement of the study.
Study design
A randomised, double-blind, placebo-controlled, parallel
study design was conducted over four menstrual cycles
(Fig. 1). Each subject commenced the study on the first
day of menstruation and subjects were requested to main-
tain their habitual dietary intake and exercise patterns. Sub-
jects assigned to the treatment group were asked to
consume two placebo tablets daily for the first cycle and
for the remaining three menstrual cycles consumed two
isoflavone tablets (Novogen Pty Ltd, North Ryde, NSW,
Australia). Isoflavones were derived from red clover and
each tablet contained 25·7 mg biochanin A, 4·3 mg genis-
tein, 9·3 mg formononetin and 3·7 mg daidzein, providing
a total intake of 86 mg isoflavones/d. Subjects assigned to
the placebo group consumed two placebo tablets daily
for all four cycles. Isoflavone and placebo tablets were
identical in appearance and contained a cellulose matrix
with 0·4 mg tocopherols as a preservative, 0·2 mg rosemary
extract and 0·4 mg rosemary oil for fragrance.
Sample collection
During menstrual cycles 1, 3 and 4, weekly venepuncture
blood samples were taken between 07.30 and 10.30 hours fol-
lowing a 10–12 h fast (Fig. 1). Blood samples were collected
into vacutainers (Becton Dickinson, Franklin Lakes, NJ,
USA), allowed to clot and then centrifuged at 1500 g for
15 min at 48C. Serum was removed and stored at 2808C
until analysis of lipids, lipoproteins, glucose and insulin.
First-morning urine samples were collected in each cycle
during the 2-week interval around ovulation (days 8–21,
where day 1 was the first day of menstruation) for analysis
of luteinising hormone to determine the day of ovulation.
Ovulation was defined as the 2 d interval in which the urin-
ary luteinising hormone:creatinine ratio rose above base-
line to reach a peak. Urine samples (24 h) were collected
at the commencement of the study and over days 5–8 of
cycles 1, 3 and 4 for isoflavone analysis. Samples were
collected in 2 litre plastic bottles that contained 1 g
ascorbic acid and were kept at 48C until delivery to the lab-
oratory. The total urine volume of each 24 h sample was
recorded. Sodium azide (1 g/l) was added as a preservative
to portions of the urine samples, which were stored
at 2808C until analysis.
Fig. 1. Study design and sample collection. The study extended over four menstrual cycles and subjects were randomly allocated to two paral-
lel groups. The placebo group consumed the placebo supplement for all four cycles. The treatment group consumed the placebo supplement
for the first cycle and continued with an isoflavone supplement (86 mg/d; Novogen Pty Ltd, North Ryde, NSW, Australia) for the remaining
three cycles. Weekly venepuncture blood samples and 4 £ 24 h urine samples were collected during cycles 1, 3, 4. First-morning urine
samples were collected for 14 d around ovulation and 3 d weighed food records were obtained in each cycle of the study.
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Compliance was assessed by counting the number of
surplus tablets returned at the end of each month and by
analysis of 24 h urinary isoflavones during cycles 1, 3
and 4. Each month of the study, subjects kept a 3 d
weighed food record. Nutrient intake was analysed using
DIET 1 software (version 4.0, 1995; Xyris Software Pty
Ltd, Highgate Hill, Queensland, Australia) and the
NUTTAB database of Australian foods (Commonwealth
Department of Community Services and Health). Initial
height and weight of volunteers were recorded to measure
BMI at the beginning of the study and body weight was
monitored on a weekly basis throughout the study.
Biochemical analyses
Serum samples were thawed and centrifuged at 1000 g for
10 min at 48C, to allow any precipitated fibrin to become
sediment. Serum total cholesterol, triacylglycerol and glu-
cose concentrations were assayed using enzymatic color-
metric assay kits (CHOD-PAP (Boehringer Mannheim,
North Ryde, NSW, Australia), Triacylglycerol PAP Unim-
ate 5 (Roche Products Pty Ltd), Glucose HK Unimate 5
(Roche Products Pty Ltd)). Total HDL-cholesterol and
HDL3-cholesterol concentrations were assayed following
dextran sulfate–magnesium chloride precipitation of
serum (Warnick et al. 1982) and HDL2-cholesterol was
calculated by difference. LDL-cholesterol was estimated
using the SI System International version (Samman &
Truswell, 1993) of the Friedewald equation (Friedewald
et al. 1972). Serum lipoprotein(a) (Lp(a)) was determined
using a turbidimetric immunoassay (Lipoprotein(a)-HA;
Wako, Osaka Japan). Lipid and glucose assays were per-
formed on a Cobas Fara II autoanalyser (Roche Diagnos-
tics, Basel, Switzerland). Serum insulin concentration
was measured using a microparticle enzyme immunoassay
and automated AxSYM system (Abbott Laboratories,
Diagnostic Division, Abbott Park, IL, USA). Homeostasis
model assessment for insulin resistance was calculated
using the equation: (fasting insulin (mU/ml) £ fasting glu-
cose (mmol/l)/22·5), as described previously (Matthews
et al. 1985). Luteinising hormone immunoradiometric
assay kit (Spectria IRMA; Orion Diagnostica, Turku,
Finland) was used to determine urinary luteinising
hormone concentrations. All samples from each subject
were measured using reagents from the same batch and
in a single run. Intra-assay CV was ,3 % for all assays.
A sample of urine (100 ml/l) from each of the four days’
collections were combined to give a composite sample for
each cycle. A 30 ml portion of the composite urine sample
was adjusted to pH 4·6 with acetic acid (700 ml/l) and phlor-
etin (75mg; Aldrich, Castle Hill, NSW, Australia) was
added as internal standard. b-Glucuronidase (100ml,
approximately 1000 Units b-glucuronidase activity, Helix
pomatia; Sigma Chemical Co, Castle Hill, NSW, Australia)
was added and the sample was incubated for 24 h at 378C.
The extent of deconjugation by the b-glucuronidase was
estimated to be 94 % using [3H]oestradiol glucuronate
(New England Nuclear Medicine, Castle Hill, NSW, Austra-
lia) (Joannou et al. 1995). Urinary isoflavones were analysed
as described previously (Franke et al. 1995) with the follow-
ing modifications. Isoflavones were extracted from urine
using a solid-phase C18 extraction cartridge (Alltech,
Baulkham Hills, NSW, Australia) activated with methanol
(5 ml) and water (5 ml). A sample of urine (10 ml) was
loaded onto the column and washed with water (5 ml).
Isoflavones were eluted from the cartridge with methanol
(3 ml, HPLC grade) and transferred to an HPLC vial for
subsequent analysis.
Isoflavone analysis was carried out on a LC-10 chro-
matograph system with an auto sampler and diode-array
detector (Shimadzu, Rydalmere, NSW, Australia). The
extract (10ml) was injected onto a C18 column (internal
diameter 5mm, 3·9 £ 150·0 mm (Nova Pac; Waters,
Milford, MA, USA)) and run at a constant temperature
of 408C using a gradient mobile phase at a flow rate of
0·9 ml/min: 300 ml A/litre B linearly to 380 ml A/litre B
in 10 min, stable at 380 ml A/litre B for 5 min then linearly
to 700 ml A/litre B for 5 min, followed by holding at
300 ml A/litre B for 10 min to equilibrate the system (A,
methanol; B, water). Isoflavones were quantified using
commercial standards, genistein, daidzein (Sigma Chemi-
cal Co), biochanin A, formononetin (Aldrich), equol,
O-desmethylangolensin, dihydrodaidzein and dihydrogen-
istein (synthesised by Dr G. E. Joannou, Children’s Hospi-
tal, Westmead, NSW, Australia). Standards were prepared
by dissolving in methanol and included in each run. The
urine samples were analysed in batches of twenty with
all samples from one subject in the same run. The mean
recovery was 93 (range 89–97) % for individual isofla-
vones. The total isoflavone concentration was corrected
for column recovery and expressed as the sum of urinary
excretion over 24 h.
Statistical analysis
Data from the follicular and luteal phase of the menstrual
cycle were averaged separately and the two phases were
compared using a paired t test. Upon verification of no sig-
nificant differences between phases, the data over the
whole cycle was averaged. Comparisons between treatment
groups were carried out using a repeated-measures general
linear model with treatment as a predictor variable,
Greenhouse–Geisser adjustments for asphericity where
necessary, and age and BMI as covariates. Statistical anal-
ysis was performed using SPSS (version 10; SPSS Inc.,
Chicago, IL, USA) with values expressed as means with
their standard errors. A level of P,0·05 was taken as stat-
istically significant without adjustment for multiple tests.
Results
Of the ninety-five women who expressed interest in parti-
cipating in the trial, thirty-one women met the selection
criteria and commenced the study. Four subjects withdrew
from the study: two cited personal reasons and two com-
menced oral contraception. In two subjects, ovulation
was not detected during the first month of the placebo sup-
plementation period and these subjects were excluded from
the statistical analysis. Characteristics of the remaining
twenty-five women included in the final statistical analysis
are given in Table 1. Baseline characteristics for the pla-
cebo and treatment groups were similar except for Lp(a),
Isoflavones, plasma lipids and insulin resistance 469
where concentrations in the placebo group were 2·3-fold
greater than for the treatment group (P¼0·01).
The mean percentage of tablets consumed by subjects, as
determined by tablet count, was similar for both groups
(97·9 (SEM 1·1) v. 98·1 (SEM 1·2) % for placebo and treat-
ment groups respectively). Analysis of total urinary isofla-
vones showed that the treatment group had a significant
ðP , 0·0001Þ 15·2–17·7-fold increase in total isoflavone
excretion during the isoflavone, compared with placebo
supplementation period (Fig. 2). In the placebo group, urin-
ary isoflavone concentrations were low at baseline and did
not change significantly during the study (Fig. 2).
Analysis of 3 d weighed food records showed that aver-
age daily intakes of energy, macronutrients and dietary
fibre were stable during the study for subjects in both
placebo and treatment groups and there were no significant
differences between the groups (Table 2). BMI was stable
throughout the study for all subjects and there were no
differences between initial and final BMI (23·2 (SEM 0·8)
v. 23·3 (SEM 0·8) kg/m2 respectively).
Seventeen of the twenty-five subjects were normocholes-
terolaemic (,5·2 mmol total cholesterol/l), while eight
subjects (four in placebo and four in the treatment group)
were mildly hypercholestaerolemic (,6·9 mmol total
cholesterol/l). Serum triacylglycerol concentrations were
within the normal range for all subjects (,2·0 mmol/l).
At baseline (cycle 1), there were no significant difference
between follicular and luteal phase concentrations of
serum lipids and lipoproteins (Table 3); there was a signifi-
cant association between serum LDL-cholesterol and Lp(a)
concentrations (r 0·69, P¼0·002).
Isoflavone supplementation had no significant effect on
mean serum lipid and lipoproteins in either normocholes-
terolaemic or mildly hypercholesterolaemic subjects
(Table 4). Lipid concentrations in the follicular and luteal
phases were not affected by isoflavone supplementation
and further adjustment for age and BMI did not alter the
outcome. The LDL-cholesterol:HDL-cholesterol was not
altered by isoflavone treatment.
There was no interaction between the magnitude of
change in serum lipids concentrations in individual sub-
jects and concomitant change in urinary isoflavones, their
metabolites or serum oestradiol during isoflavone sup-
plementation. Serum concentrations of insulin and glucose,
and HOMA-IR were unaffected by isoflavone supplemen-
tation (Table 4).
Discussion
Young women were selected for this study as part of a
broader investigation aimed at determining the effect of
isoflavones on risk factors for breast cancer. Since the puta-
tive mechanism of action involves oestrogen metabolism,
we also investigated the effect on plasma lipids, since
they are regulated by oestrogen. In a previous crossover
study design, we showed that plasma HDL3-cholesterol
concentrations increased after 2 months supplementation
with purified isoflavones derived from red clover
(Samman et al. 1999). However, these findings were
inconclusive as we observed a period and carryover
effect. To address these issues in the present study, we
used a randomised parallel design to remove the possibility
of a carryover effect, and extended the period of isoflavone
supplementation to 3 months. Our present results show that
markers of insulin resistance and the concentration of
serum cholesterol and its distribution amongst lipoproteins
are unaffected by isoflavone supplementation.
That the lack of effect is due to poor compliance is unli-
kely, since the mean urinary isoflavone concentrations
increased by 15-fold during isoflavone supplementation.
At the same time, isoflavone excretion during the placebo
period remained low, indicating that little or no foods
containing isoflavones were consumed. Consistent with
previous studies in which red clover (Samman et al.
1999) or soyabean products (Kelly et al. 1995) were
used as the source of isoflavones, large inter-individual
variation in isoflavone excretion was observed. The extent
of isoflavone excretion could indicate an individual’s
Table 1. Characteristics of subjects at baseline
(Mean values with their standard errors)
Placebo group
(n 13)
Treatment
group (n 12)
Mean SEM Mean SEM
Age (years) 32·5 2·6 32·8 2·9
Weight (kg) 61·0 3·7 63·6 3·4
Height (m) 1·61 0·02 1·66 0·03
BMI (kg/m2) 23·4 1·2 23·0 1·2
Menstrual cycle length (d) 30·0 2·1 29·4 1·5
Total cholesterol (mmol/l) 4·9 0·3 4·7 0·3
HDL-cholesterol (mmol/l) 1·5 0·1 1·5 0·1
LDL-cholesterol (mmol/l) 2·9 0·3 2·9 0·2
Triacylglycerol (mmol/l) 1·2 0·2 0·9 0·1
Lipoprotein(a) (mg/l) 519 85 226** 66
Mean value as significantly different from that of the placebo group: **P=0·01.
Fig. 2. Effect of isoflavone supplement (86 mg/d; (Novogen Pty Ltd,
North Ryde, NSW, Australia) or placebo on concentrations of total
urinary isoflavones. Total isoflavones concentrations are expressed
as the sum of genistein, daidzein, biochanin A, formononetin, equol,
O-desmethylangolensin, dihydrodaidzein and dihydrogenistein. V,
Treatment group; W, placebo group. For details of subjects, supple-
ments and procedures, see Table 1 and p. 468. Values are means
with their standard errors shown by vertical bars. In the placebo
group (n 13) there was no significant change in total urinary isofla-
vone concentrations. Mean values in the treatment group (n 12)
were significantly different during cycles 3 and 4 (isoflavone sup-
plementation) than in cycle 1 (placebo supplementation):
****P,0·0001).
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capacity to absorb and utilise isoflavones. Therefore, the
potential oestrogenic impact on the lipoprotein profile
could be greatest in those individuals who excrete high
levels of isoflavones. However, no relationship was
observed between the magnitude of isoflavone excretion
and serum lipoproteins.
Our present findings were consistent with previous inter-
vention studies, in which differing study populations
consumed a range of isoflavone formulations. Normocho-
lesterolaemic men and postmenopausal women were sup-
plemented with 55 mg isoflavones/d derived from red
clover for 8 weeks and showed no change in plasma lipids
and lipoproteins (Hodgson et al. 1998). Howes et al.
(2000) and Nestel et al. (1999), studying a group of
mildly hypercholesterolaemic postmenopausal women,
used a formulation of red clover-derived isoflavone tablets
similar to those used in the present study (4·0 mg genistein,
3·5 mg daidzein, 24·5 mg biochanin A and 8·0 mg formono-
netin per tablet) and failed to demonstrate any cholestero-
laemic effects after 5 weeks of supplementation with
doses of 40 and 80 mg/d. In other studies, purified isofla-
vones derived from soyabean (containing genistein, daid-
zein and glycitein) did not result in any alterations in lipid
levels when consumed by postmenopausal women (Nestel
et al. 1997; Simons et al. 2000). The doses consumed in
these studies, regardless of their source, were equivalent
to intakes in a Japanese population, where consumption of
similar quantities of isoflavones in soybeans and related pro-
ducts was associated with decreased serum total cholesterol
concentrations (Nagata et al. 1997).
The absence of change in serum lipids during sup-
plementation with purified isoflavones derived from
either red clover or soyabean, is in contrast to the findings
of interventions with isoflavones intact within a soyabean-
protein matrix. Isoflavone-rich soyabean protein has
resulted in a reduction in plasma cholesterol by 10·0 % or
LDL-cholesterol levels by 7·6–10·0 % in normocholestero-
laemic premenopausal women (Cassidy et al. 1994, 1995;
Merz-Demlow et al. 2000). In hypercholesterolaemic
men and postmenopausal women, a dose-dependent
response was observed, in that LDL-cholesterol and total
cholesterol were lowered with increasing concentrations
of isoflavones within a soyabean protein matrix (Crouse
et al. 1999). Further, plasma lipids were not altered by
consumption of isoflavone-free soyabean protein, confirm-
ing an active role for the isoflavone constituents in the
soyabean protein. However, soyabean isoflavones failed
to show an effect on lipids in premenopausal women,
Table 2. Intake of macronutrients and dietary fibre in the placebo and treatment groups during the study
of premenopausal women*†
(Mean values with their standard errors)
Placebo group (n 13) Treatment group (n 14)
Cycle 1 Cycle 4 Cycle 1 Cycle 4
Nutrient Mean SEM Mean SEM Mean SEM Mean SEM
Energy (MJ/d) 8·2 0·4 7·6 0·4 8·2 0·3 8·0 0·4
Carbohydrate (% energy) 46·8 2·3 49·3 2·1 50·8 2·1 49·1 1·6
Protein (% energy) 16·2 0·9 17·4 1·1 16·0 1·0 16·7 1·1
Total fat (% energy) 33·1 2·2 30·1 1·7 31·5 2·3 33·0 1·4
PUFA:SFA 0·50 0·17 0·45 0·20 0·45 0·21 0·52 0·25
Alcohol (% energy) 3·8 1·8 3·2 1·4 1·4 0·6 1·1 0·6
Dietary fibre (g/d) 23·4 2·5 23·6 3·4 27·2 2·6 27·5 4·1
PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids.
* For details of subjects, supplements and procedures, see Table 1 and p. 468.
† Values represent means for 3 d during each cycle. There were no significant changes in dietary intakes during the
study.
Table 3. Effect of the menstrual cycle phase on mean serum lipid and lipoproteins at
baseline (cycle 1) in premenopausal women*
(Mean values with their standard errors for twenty-five women)
Follicular phase†‡ Luteal phase‡
Mean SEM Mean SEM
Triacylglycerol (mmol/l) 1·00 0·10 1·00 0·10
Total cholesterol (mmol/l) 4·85 0·21 4·78 0·22
HDL-cholesterol (mmol/l) 1·46 0·06 1·45 0·05
HDL3-cholesterol (mmol/l) 1·00 0·03 1·04 0·03
HDL2-cholesterol (mmol/l) 0·46 0·07 0·44 0·06
LDL-cholesterol (mmol/l) 2·94 0·18 2·88 0·19
LDL-cholesterol:HDL-cholesterol 2·08 0·15 2·03 0·15
Lipoprotein(a) (mg/l) 361 63 349 62
* For details of subjects and procedures, see Table 1 and p. 468.
† Includes values at time of ovulation.
‡ There were no significant differences in lipids and lipoprotein concentrations between the follicu-
lar and leuteal phases.
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possibly because sampling did not control for endogenous
variations of lipids (Lyons Wall et al. 1994; Crouse et al.
1999). Similarly, in ovariectomized cynomolgus monkeys
(Macaca fascicularis), isoflavone-rich soyabean protein
resulted in lower cholesterol levels whereas an isofla-
vone-rich ethanol extract, added to casein, did not improve
plasma lipids (Greaves et al. 1999). These results suggest
that an interaction between soyabean protein and one or
more components in the ethanol extract, such as isofla-
vones or saponins, are needed for the hypocholesterolaemic
effects to occur. Another possible explanation is that the
isoflavones per se are not the lipid-lowering component
of soyabean protein. For example, soyabean globulins
may be able to alter cholesterol homeostasis (Sirtori et al.
1997; Lovati et al. 2000) and removal of isoflavones from
soyabean protein by ethanol extraction could alter the func-
tional integrity of these polypeptides.
In the present trial, the length of isoflavone supplemen-
tation was increased to three menstrual cycles, compared
with the previous two-cycle trial that we conducted
(Samman et al. 1999), to permit investigation of possible
longer-term changes that could arise indirectly via effects
of isoflavones on hormones such as oestradiol. Oestrogens
can influence HDL-cholesterol levels by inhibiting activity
of hepatic lipase and stimulating synthesis of apolipoprotein
A-I (Muesing et al. 1992; Brinton, 1996; Lamon-Fava et al.
1999). However, we did not observe any associations
between the change in oestradiol and HDL-cholesterol
concentrations or any other lipid or lipoprotein (results not
shown). By sampling at weekly intervals during the men-
strual cycle, our analysis also took into account menstrual
fluctuations in lipids and lipoproteins, and thus the lack of
effect of the isoflavone supplement was not due to counter-
action by cyclic variation of lipids. We also observed that
isoflavone supplementation did not adversely affect glucose,
insulin and the homeostasis model assessment for insulin
resistance, a surrogate measure of insulin resistance
(Matthews et al. 1985). The lack of change in insulin was
consistent with the observation that serum triacylglycerol
or HDL-cholesterol concentrations were not altered.
Lp(a) has been identified as an independent risk factor
for CHD (Dahlen, 1994). Although oestrogens have been
shown to reduce serum Lp(a), the mechanism of action is
unknown (Haines et al. 1996). It has been reported that
Lp(a) concentrations increased by 20 % when soyabean
protein was substituted for casein as part of a liquid diet
consumed by normocholesterolaemic men (Nilausen &
Meinertz, 1999). This was in contrast to the finding of
Anthony et al. (1996), where isoflavone-rich soyabean-pro-
tein isolate, compared with isoflavone-free soyabean pro-
tein, reduced Lp(a) concentrations by 18 % in female but
not male primates. In the present study, we showed that
purified isoflavones from red clover have no effect on
Lp(a) levels.
Purified isoflavones are being investigated as a way of
modifying the risk of breast cancer in premenopausal
women. Our present results indicate that such a strategy
is unlikely to increase the risk of CHD as indicated by a
lack of effect on insulin resistance and plasma lipoproteins.
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